Potent antagonism by BIM-23056 at the human recombinant somatostatin sst5 receptor

Br J Pharmacol. 1996 Jun;118(3):445-7. doi: 10.1111/j.1476-5381.1996.tb15423.x.

Abstract

We have investigated the effects of somatostatin (SRIF) and the linear octapeptide BIM-23056 on changes in intracellular calcium ion concentration ([Ca2+]i) and on the formation of inositol-1,4,5-trisphosphate (Ins(1,4,5)P3) in CHO-K1 cells transfected with the human recombinant SRIF sst5 receptor. SRIF elicited concentration-dependent increases in [Ca2+]i, with a pEC50 of 7.02 +/- 0.06, while BIM-23056 (1 x 10(-7) M) behaved not as an agonist but as a potent, surmountable antagonist of these increases in [Ca2+]i. The SRIF concentration-effect curve for increases in [Ca2+]i was shifted rightward producing an estimated pKB for the antagonist of 8.0. BIM-23056 (1 x 10(-7) M) also significantly attenuated Ins(1,4,5)P3 increases due to SRIF, but had no effect on either basal or uridine 5'-triphosphate (UTP) (1 x 10(-4) M) stimulated increases in the levels of [Ca2+]i or Ins(1,4,5)P3.

MeSH terms

  • Animals
  • CHO Cells / drug effects
  • Calcium / metabolism*
  • Cricetinae
  • Dose-Response Relationship, Drug
  • Humans
  • Oligopeptides / pharmacology*
  • Receptors, Somatostatin / antagonists & inhibitors*
  • Recombination, Genetic
  • Somatostatin / pharmacology*
  • Uridine Triphosphate / pharmacology

Substances

  • BIM 23056
  • Oligopeptides
  • Receptors, Somatostatin
  • Somatostatin
  • Calcium
  • Uridine Triphosphate